OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOWING REDUCED-INTENSITY CONDITIONINIG REGIMEN IN PATIENTS WITH IDIOPATHIC MYELOFIBROSIS: THE G.I.T.M.O. EXPERIENCE AND REVIEW OF THE LITERATURE

OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOWING REDUCED-INTENSITY CONDITIONINIG REGIMEN IN PATIENTS WITH IDIOPATHIC MYELOFIBROSIS: THE G.I.T.M.O. EXPERIENCE AND REVIEW OF THE LITERATURE

Show other versions (1)

<p class="MsoBodyText" style="margin: 0cm 0cm 0pt;"><strong style="mso-bidi-font-weight: normal;"><em style="mso-bidi-font-style: normal;"><span style="mso-ansi-language: IT;"><span style...

Full description

Saved in:

Bibliographic Details
Main Authors:	Miriam Isola, Alessandra Sperotto, Andrea Bacigalupo, Francesca Patriarca, Maria Teresa Van Lint, Anna Paola Iori, Paolo Di Bartolomeo, Maurizio Musso, Pietro Pioltelli, Giuseppe Visani, Pasquale Iacopino, Renato Fanin, Alberto Bosi
Format:	Article
Language:	English
Published:	PAGEPress Publications 2010-05-01
Series:	Mediterranean Journal of Hematology and Infectious Diseases
Subjects:	Myelofibrosis Hemopioetic Stem Cell Translantation Reduced Intensity Conditionin Regimen
Online Access:	http://www.mjhid.org/article/view/5907
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOWING REDUCED-INTENSITY CONDITIONINIG REGIMEN IN PATIENTS WITH IDIOPATHIC MYELOFIBROSIS: THE G.I.T.M.O. EXPERIENCE AND REVIEW OF THE LITERATURE
by: Francesca Patriarca, et al.
Published: (2010-05-01)

IS ALLOGENEIC TRANPLANTATION AN OPTION IN PATIENTS AFFECTED BY CONCURRENT MYELOFIBROSIS AND CHRONIC MYELOID LEUKEMIA (CML)?
by: Federica Sorà, et al.
Published: (2021-10-01)

IRON CHELATION THERAPY WITH DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PRIMARY MYELOFIBROSIS
by: Elena Maria Elli, et al.
Published: (2014-05-01)

Treatment Strategies Used in Treating Myelofibrosis: State of the Art
by: Massimo Martino, et al.
Published: (2024-10-01)

Lactate accumulation promotes immunosuppression and fibrotic transformation of bone marrow microenvironment in myelofibrosis
by: Mariarita Spampinato, et al.
Published: (2025-01-01)

Presence of triple positive driver mutations in JAK2, CALR and MPL in primary myelofibrosis: a case report and literature review
by: Long Zhao, et al.
Published: (2024-12-01)

Analysis of MicroRNA -155-5p Expression in Patients with Primary Myelofibrosis.
by: Sarah I. Khaleel, et al.
Published: (2024-12-01)

Successful treatment of pyoderma gangrenosum complicated by JAK2V617F mutation-positive myelofibrosis with adalimumab and systemic steroid
by: Kyohei Shibuta, et al.
Published: (2025-01-01)

Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis
by: Stine Ulrik Mikkelsen, et al.
Published: (2018-08-01)

Inhibition of JAK2 and MDM2 to treat secondary acute myeloid leukemia evolving from myelofibrosis
by: Fuping Wang, et al.
Published: (2024-12-01)

A comparative retrospective study of pre-fibrotic primary myelofibrosis versus overtly fibrotic stage in Qatar: clinicopathological, genetic landscape, risk stratification and survival data (2008–2021) – a single center experience
by: Sarah A. ElKourashy, et al.
Published: (2024-12-01)

Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial
by: Graham McIlroy, et al.
Published: (2025-01-01)

RUNX1::CBFA2T2 rearranged acute myeloid leukemia transformed from JAK2 V617F mutated primary myelofibrosis
by: Lina Han, et al.
Published: (2024-12-01)

MPN in the guise of nutritional deficiency
by: Veda P
Published: (2014-08-01)

The characteristics of CALR mutations in myeloproliferative neoplasms: a clinical experience from a tertiary care center in Qatar and a literature review
by: Mostafa Najim, et al.
Published: (2024-12-01)

Bone marrow fibrosis – the basis of mielofibrosis: pathogenesis, prognostication and antifibrogenic targeted strategies.
by: A. S. Timchenko, et al.
Published: (2018-04-01)

Reconstructing skeletal homeostasis through allogeneic hematopoietic stem cell transplantation in myelofibrosis
by: Mathias Schäfersküpper, et al.
Published: (2025-01-01)

Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan
by: Yoko Edahiro, et al.
Published: (2024-12-01)

Eosinophilia with STAT5BN642H Mutation: A Heterogeneous Entity with Overlapping Morphological Features and Poor Outcome
by: Venkat Chittapragada, et al.
Published: (2024-12-01)

Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy
by: Pasquale Niscola
Published: (2013-04-01)

Novel approaches in myelofibrosis
by: Steffen Koschmieder
Published: (2024-12-01)

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA OF THE ELDERLY: REVIEW OF THE LITERATURE AND PERSPECTIVES.
by: Gabriele Magliano, et al.
Published: (2020-10-01)

Chronic Lymphocytic Leukemia and Myelofibrosis
by: Fares Darawshy, et al.
Published: (2018-01-01)

TREATMENT OF MYELOFIBROSIS: PRESENT AND FUTURE
by: Birsen Sahip Yesiralioğlu
Published: (2024-12-01)

Elevated Vitamin B12 Levels in Myeloproliferative Neoplasm (MPN) Patients: A Potential Diagnostic and Prognostic Marker
by: Fadul A, et al.
Published: (2024-12-01)

Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation of JAK2 V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell Transplantation
by: Stephen E. Langabeer, et al.
Published: (2015-01-01)

Successful Control of Acute Myelofibrosis with Lenalidomide
by: G. Vassilopoulos, et al.
Published: (2010-01-01)

Dermatomyositis Associated with Myelofibrosis following Polycythemia Vera
by: Naomi Fei, et al.
Published: (2017-01-01)

Insights into the role of JAK2-I724T variant in myeloproliferative neoplasms from a unique cohort of New Zealand patients
by: Christopher Puli'uvea, et al.
Published: (2024-12-01)

Assessing the contribution of myelofibrosis to a leukoerythroblastic blood picture
by: Stephen E. Langabeer
Published: (2025-01-01)

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib
by: Maheen Z. Abidi, et al.
Published: (2016-01-01)

Primary myelofibrosis progression: a game of cellular telephone
by: Lucas Wadley, et al.
Published: (2025-01-01)

Acute Panmyelosis with Myelofibrosis - A Rare Subtype of Acute Myeloid Leukemia
by: Tathagata Chatterjee, et al.
Published: (2013-06-01)

Systemic lupus erythematosus presenting as autoimmune myelofibrosis and acquired hemophilia A
by: Mansoor C Abdulla
Published: (2021-01-01)

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THERAPY-RELATED MYELOID NEOPLASMS (t-MN) OF THE ADULT: MONOCENTRIC OBSERVATIONAL STUDY AND REVIEW OF THE LITERATURE.
by: Elisabetta Metafuni, et al.
Published: (2018-01-01)

Myelofibrosis-Associated Lymphoproliferative Disease: Retrospective Study of 16 Cases and Literature Review
by: A. Etienne, et al.
Published: (2009-01-01)

Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain
by: María Teresa Gómez-Casares, et al.
Published: (2017-11-01)

Fedratinib for the treatment of myelofibrosis: a critical appraisal of clinical trial and “real-world” data
by: Adrian Duek, et al.
Published: (2025-01-01)

Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib
by: Keith L. Davis, et al.
Published: (2015-01-01)

Prefibrotic Myelofibrosis Presenting with Multiple Cerebral Embolic Infarcts and the Rare MPL W515S Mutation
by: Stephen E. Langabeer, et al.
Published: (2020-01-01)